Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Socratech LLC
Profile last edited on: 5/14/14      CAGE: 4PVB5      UEI:

Business Identifier: therapeutics neurodegenerative disorders such as Alzheimers disease and stroke
Year Founded
2000
First Award
2004
Latest Award
2010
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

601 Elmwood Avenue Box 670
Rochester, NY 14642
   (585) 275-4233
   N/A
   www.socratech.org
Location: Single
Congr. District: 25
County: Monroe

Public Profile

Socratech L.L.C. is a biotechnology company with the primary focus on discovery and development of therapeutics for the treatment of neurodegenerative disorders such as Alzheimers disease and stroke. Alzheimer's disease is the fourth leading cause of death. Alzheimers Disease is a devastating brain disorder associated with fatal cognitive impairment, mental disability and progressive degeneration of brain cells in elderly population. Stroke is the third leading cause of death associated with degeneration of brain cells and neurological disabilities

Extent of SBIR involvement

User Avatar
Phase I Awards
6
Phase II Awards
1
Conversion Rate
16.67%
Phase I Dollars
$635,925
Phase II Dollars
$1,084,494
Total Awarded
$1,720,419

Synopsis: Awardee Business Condition

Employee Range
20-24
Revenue Range
2M-2.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2010 1 NIH $100,000
Project Title: Enhance Production Of Functional Recombinant Human Protein C Variant In Mammalian
2009 2 NIH $1,185,783
Project Title: SRF/MYOCD: new targets in Alzheimer's neurovasculature
2008 1 NIH $120,636
Project Title: Recombinant Lrp Fragments Production For Alzheimer?S Disease Treatment
2004 1 NIH $107,000
Project Title: Target Assessment in Alzheimer's Neurovasculature/BBB
2004 1 NIH $100,000
Project Title: Small Arteries as a Therapeutic Target in AD

Key People / Management

  Nienwen Chow

  Rashid Deane

  Jamila Ibrahim

  Joseph M Miano

  Jan F Sallstrom

  Berislav V Zlokovic -- Chief Scientific Officer

Company News

 UR Researcher Forms Biotech Company to Develop New Class of Alzheimers Treatments - URMC Press Room